Combining HDAC Inhibitors With Immunotherapy in Melanoma
September 7th 2018Sanjiv S. Agarwala, MD, chairman of medical oncology at St. Luke’s University Health Network, discusses the combination of immunotherapy and a histone deacetylase inhibitor in patients with melanoma, as well as other types of cancer.